European trials and the management of prostate cancer

Seminars in Surgical Oncology

Volumn 11, Issue 1, 1995, Pages 65-71

  Newling, D W W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

androgen blockade; chemotherapy; estrogen therapy; novel therapies

Indexed keywords

BUSERELIN; CYPROTERONE ACETATE; FLUTAMIDE; GOSERELIN; MITOMYCIN C; STRONTIUM CHLORIDE;

ADVANCED CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; ESTROGEN THERAPY; EUROPE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; EUROPE; HORMONES; HUMAN; INCIDENCE; MALE; NEOPLASM STAGING; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL;

EID: 0028855049     PISSN: 87560437     EISSN: 10982388     Source Type: Journal    
DOI: 10.1002/ssu.2980110110     Document Type: Article

References (29)

1. Latent carcinoma of the prostate
2. The Veterans Administration Cooperative Urological Research Groups studies of cancer of the prostate
3. Multivariate analysis of outcome following observation—delayed therapy of clinically localized prostatic cancer
4. The natural history of prostatic cancer, the argument for a no treatment policy
5. Watchful waiting for early stage prostate cancer
6. 1986. Comparison DES, CPA and MPA in the treatment of advanced prostatic cancer—final analysis of a randomized phase III trial of EORTC urological group
7. Comparison of the effects of DES with low dose Estramustine phosphate in the treatment of advanced prostate cancer—final analysis of a phase III trial of the EORTC Urological group
8. Le Cancer du prostate
9. Treatment of advance localises prostate cancer by orchiectomy, radiotherapy, or combined treatment
10. New concepts in the treatment of stage Dl adenocarcinoma of the prostate
11. Extended experience with surgical treatment of stage Dl adenocarcinoma of the prostate
12. A new approach in the hormonal treatment of prostate cancer: complete instead of partial blockade of androgens
13. EORTC protocol 30805: A phase III trial comparing orchiectomy versus orchiectomy and CPA and low dose stilboestrol in the management of metastatic carcinoma of the prostate
14. Short term vs. long term addition of CPA to Buserelin therapy in comparison with orchiectomy for metastatic prostatic cancer (EORTC trial 30843)
15. A controlled trial of Luprolyte with and without Flutamide in pro‐static carcinoma
16. Goserelin acetate and Flutamide vs. bilateral orchiectomy: a phase III EORTC trial (30853)
17. Zoladex and Flutamide vs. orchiectomy in the treatment of patients with advanced carcinoma of the prostate, a phase III trial
18. Maximal androgen blockade—an overview
19. Cardiovascular side effects of die‐thylstibestrol, CPA, MPA and estramustine phosphate used for the treatment of advanced prostatatic cancer: results for EORTC trials 30761 and 30762
20. Influence of treatment with diethylbestrol for carcinoma of prostate on platelet aggregation and plasma lipoproteins
21. Casodex: the phase II results
22. Intermittent an‐drogen suppression in patients with metastatic prostate cancer
23. Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer
24. Chemotherapy for prostatic carcinoma
25. Mitomycin C vs. estramustine in the treatment of hormone resistant metastatic prostatic cancer
26. Orchiectomy versus Goserelin and Flutamide in the treatment of newly diagnosed metastatic prostate cancer
27. A prospective randomized controlled study on the treatment of stage D and C prostatic cancer with Estracyt in combination with other therapeutic agents